Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Lilly

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.

Lilly

China: AstraZeneca’s new engine for growth and innovation

China: AstraZeneca’s new engine for growth and innovation

Growing confidence in China as an R&D centre. While some companies have pared back their investment in China research and development in recent years (such as GSK and Lilly), AstraZeneca

Lilly gets EMA nod for Verzenio in breast cancer

Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer. And puts pressure on Pfizer’s market leading Ibrance and Novartis’Kisqali. ... women. It’s not all been plain sailing for Lilly’s CDK4/6 inhibitor programme however.

Novo Nordisk to launch connected insulin pens

Novo Nordisk to launch connected insulin pens Novo Nordisk’s biggest competitors in diabetes injectables are Eli Lilly and Sanofi, but looks to be ahead of its rivals in rolling out a joined-up digital solution, announcing plans ... Meanwhile, rival Eli Lilly is developing its own Connected

China’s Innovent to start US trials of anti-CD47 cancer drug

China’s Innovent to start US trials of anti-CD47 cancer drug trials after PD-1 inhibitor sintilimab (IBI-308) – partnered with Eli Lilly – got a green light earlier this year.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics